학술논문
Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients
Document Type
article
Author
Raphael Romano Bruno; Bernhard Wernly; Hans Flaatten; Jesper Fjølner; Antonio Artigas; Bernardo Bollen Pinto; Joerg C. Schefold; Stephan Binnebössel; Philipp Heinrich Baldia; Malte Kelm; Michael Beil; Sivri Sigal; Peter Vernon van Heerden; Wojciech Szczeklik; Muhammed Elhadi; Michael Joannidis; Sandra Oeyen; Tilemachos Zafeiridis; Jakob Wollborn; Maria José Arche Banzo; Kristina Fuest; Brian Marsh; Finn H. Andersen; Rui Moreno; Susannah Leaver; Ariane Boumendil; Dylan W. De Lange; Bertrand Guidet; Christian Jung; the COVIP Study Group
Source
Annals of Intensive Care, Vol 11, Iss 1, Pp 1-9 (2021)
Subject
Language
English
ISSN
2110-5820
Abstract
Abstract Purpose Lactate is an established prognosticator in critical care. However, there still is insufficient evidence about its role in predicting outcome in COVID-19. This is of particular concern in older patients who have been mostly affected during the initial surge in 2020. Methods This prospective international observation study (The COVIP study) recruited patients aged 70 years or older (ClinicalTrials.gov ID: NCT04321265) admitted to an intensive care unit (ICU) with COVID-19 disease from March 2020 to February 2021. In addition to serial lactate values (arterial blood gas analysis), we recorded several parameters, including SOFA score, ICU procedures, limitation of care, ICU- and 3-month mortality. A lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline) was defined as abnormal. The primary outcome was ICU-mortality. The secondary outcomes 30-day and 3-month mortality. Results In total, data from 2860 patients were analyzed. In most patients (68%), serum lactate was lower than 2 mmol/L. Elevated baseline serum lactate was associated with significantly higher ICU- and 3-month mortality (53% vs. 43%, and 71% vs. 57%, respectively, p